NFKB1 and neoplasm: NLRP12 is another potential therapeutic target, since NLRP12 knockout mice looks prone to colon inflammation and CRC, through enhanced activity of non-canonical NF-κB, ERK and AKT pathways, in both macrophages and tumor cells [181,182].